Skip to main content

Advertisement

SpringerLink
Log in

ASO Author Reflections: To Test or Not to Test: How Do We Decide the Optimal Site for Organoid Generation in Patients with Metastatic Disease?

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kopper O, de Witte CJ, Lõhmussaar K, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med. 2019;25:838–49. https://doi.org/10.1038/s41591-019-0422-6.

    Article  CAS  PubMed  Google Scholar 

  2. Forsythe SD, Sasikumar S, Moaven O, et al. Personalized identification of the optimal HIPEC perfusion protocol in patient-derived tumor organoid platform. Ann Surg Oncol. 2020;27(13):4950–4960. https://doi.org/10.1245/s10434-020-08790-2.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Votanopoulos KI, Mazzocchi A, Sivakumar H, et al. Appendiceal cancer patient-specific tumor organoid model for predicting chemotherapy efficacy prior to initiation of treatment: a feasibility study. Ann Surg Oncol. 2019;26:139–47. https://doi.org/10.1245/s10434-018-7008-2.

    Article  PubMed  Google Scholar 

  4. Radomski SN, Dunworth M, West JJ, et al. Intra- and interpatient drug response heterogeneity exist in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for non-gynecologic cancers. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-023-14696-6.

    Article  PubMed  Google Scholar 

  5. Flood M, Narasimhan V, Wilson K, et al. Organoids as a robust preclinical model for precision medicine in colorectal cancer: a systematic review. Ann Surg Oncol. 2022;29(1):47–59. https://doi.org/10.1245/s10434-021-10829-x.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Johns Hopkins Medical School, Baltimore, MD, USA

    Shannon N. Radomski MD, Jonathan B. Greer MD & Fabian M. Johnston MD, MHS

  2. Department of Cell Biology, Johns Hopkins Medical School, Baltimore, MD, USA

    Shannon N. Radomski MD & Andrew J. Ewald PhD

  3. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA

    Fabian M. Johnston MD, MHS & Andrew J. Ewald PhD

  4. Giovanis Institute for Translational Cell Biology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Andrew J. Ewald PhD

Authors
  1. Shannon N. Radomski MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan B. Greer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fabian M. Johnston MD, MHS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrew J. Ewald PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew J. Ewald PhD.

Ethics declarations

Disclosure

The authors received support from the NIH/NCI 5T32CA126607 (S.N.R.), NIH/NCI U54CA268083 (A.J.E.), the American College of Surgeons Resident Research Scholarship (S.N.R.), the Commonwealth Foundation for Cancer Research (F.M.J., A.J.E.), the Johns Hopkins SPORE in Gastrointestinal Cancer at the Sidney Kimmel Comprehensive Cancer Center (S.N.R., A.J.E.), the Giovanis Institute for Translational Cell Biology (A.J.E.). Andrew J. Ewald has unlicensed patents related to keratin 14 as a prognostic marker and to antibody strategies for anti-cancer therapeutics. He is a consultant for BioNTech, and his spouse is an employee of ImmunoCore. The remaining authors have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article refers to: Radomski SN, Dunworth M, West JJ, et al. Intra- and interpatient drug response heterogeneity exist in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for non- gynecologic cancers. Ann Surg Oncol. 2023. https://doi.org/https://doi.org/10.1245/s10434-023-14696-6.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Radomski, S.N., Greer, J.B., Johnston, F.M. et al. ASO Author Reflections: To Test or Not to Test: How Do We Decide the Optimal Site for Organoid Generation in Patients with Metastatic Disease?. Ann Surg Oncol 31, 2403–2404 (2024). https://doi.org/10.1245/s10434-023-14887-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-023-14887-1

Search

Navigation